Every Form 4 that Foghorn Therapeutics Inc. (FHTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FHTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FHTX filings page.
Foghorn Therapeutics Inc. director Thomas J. Lynch Jr. received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, conditioned on his continued service on the board of directors, and expire on June 23, 2036. Following this grant, he holds options for 28,000 underlying shares directly.
Foghorn Therapeutics Inc. director Stuart Duty received a grant of stock options to buy 28,000 shares of Common Stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, subject to his continued board service, and expire on June 23, 2036. Following this grant, Duty holds 28,000 stock options directly.
Foghorn Therapeutics director Scott Biller received a stock option grant covering 28,000 shares of common stock at an exercise price of $4.08 per share. The option was granted as compensation and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. Following this award, Biller holds 28,000 stock options directly.
Foghorn Therapeutics Inc. director Neil Gallagher received a grant of stock options as part of his compensation. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. After this grant, he holds 28,000 stock options directly, which are scheduled to expire on June 23, 2036. This is a compensation-related award, not an open-market purchase or sale.
Foghorn Therapeutics director Michael Mendelsohn received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options were awarded as compensation and give him the right to buy shares at that price in the future.
The options vest in full on the first anniversary of the grant date, as long as he continues to serve on the board of directors. After this grant, he holds 28,000 stock options directly, with an expiration date in 2036, providing long-term equity-based incentives tied to the company’s share performance.
Foghorn Therapeutics Inc. director Ian F. Smith received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. Following this compensation award, Smith holds 28,000 options directly, and the filing reports no open-market buying or selling activity.
Foghorn Therapeutics Inc. director Simba Gill received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, subject to continued service on the board, and expire on June 23, 2036. Following this award, Gill holds 28,000 stock options directly.
Foghorn Therapeutics Inc. director Lynne B. Parshall received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.08 per share and expire on June 23, 2036. Following this grant, she holds 28,000 options directly. According to the terms, the option vests in full on the first anniversary of the grant date, assuming she continues to serve on the board of directors.
Foghorn Therapeutics director Douglas G. Cole received a compensation-related stock option grant. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, as long as he continues serving on the board. Following this grant, he holds 28,000 stock options, which are scheduled to expire on June 23, 2036.
Foghorn Therapeutics Inc. Chief Executive Officer Adrian Gottschalk reported a series of bona fide gifts of Common Stock between family estate-planning vehicles. On April 9 and 10, 2026, four indirect transactions moved a total of 213,410 shares among grantor retained annuity trusts and his Living Trust at a stated price of $0.00 per share.
The 2023 Grantor Retained Annuity Trust distributed 47,497 shares to the Adrian H. Gottschalk Living Trust, leaving the 2023 GRAT with 0 shares and the Living Trust with 211,704 shares indirectly held. Separately, the 2025 Grantor Retained Annuity Trust distributed 59,208 shares to the Living Trust, after which the 2025 GRAT held 240,792 shares and the Living Trust held 270,912 shares, all reported as indirect ownership. These movements are characterized as gift transfers rather than open-market trades.
Foghorn Therapeutics Inc. reported that Chief Financial Officer Ryan D. Maynard was granted a stock option to acquire 400,000 shares of common stock at an exercise price of $5.75 per share. The option vests 25% on February 23, 2027, then 6.25% quarterly until fully vested.
Foghorn Therapeutics Inc. Chief Executive Officer and director Adrian Gottschalk received a new stock option grant. On February 5, 2026, he was awarded an option to purchase 1,075,000 shares of Foghorn Therapeutics common stock at an exercise price of $5.23 per share.
The option vests as to 25% of the underlying shares on February 5, 2027, then 6.25% of the shares vest on the first day of each calendar quarter thereafter. Following this grant, Gottschalk beneficially owns 1,075,000 derivative securities directly.
Foghorn Therapeutics granted Chief People Officer Carlos Costa a stock option award covering 230,000 shares of common stock on January 30, 2026. The option has an exercise price of $5.71 per share and is held directly by Costa.
The option vests over time: 25% of the underlying shares vest on January 30, 2027, with the remaining shares vesting at a rate of 6.25% of the underlying shares on the first day of each calendar quarter thereafter. Following this grant, Costa beneficially owns stock options for 230,000 shares.
Foghorn Therapeutics reported that Chief Legal Officer Michael LaCascia received an award of stock options covering 295,000 shares of common stock at an exercise price of $5.71 per share on January 30, 2026. The option vests 25% on January 30, 2027, then 6.25% of the underlying shares on the first day of each calendar quarter, aligning his compensation with the company’s future share performance.
Foghorn Therapeutics Inc. reported that its Chief Medical Officer, Alfonso Quintas-Cardama, received a grant of stock options on January 30, 2026. The award covers 300,000 stock options with an exercise price of $5.71 per share.
The options relate to common stock and are held directly. Vesting is structured so that 25% of the underlying shares vest on January 30, 2027, with the remaining options vesting at 6.25% of the underlying shares on the first day of each calendar quarter until fully vested. The options expire on January 29, 2036 if not exercised.
Foghorn Therapeutics granted Chief Business Officer Anna Rivkin a stock option to buy 165,000 shares of common stock at $5.71 per share on January 30, 2026. This option is held directly by Rivkin.
The option vests over time: 25% of the underlying shares vest on January 30, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% of the underlying shares on the first day of each calendar quarter. The option expires on January 29, 2036 if not exercised.
Foghorn Therapeutics Inc. reported that Chief Scientific Officer Steven F. Bellon received a stock option grant covering 300,000 shares of common stock at an exercise price of $5.71 per share on January 30, 2026. The option vests 25% on January 30, 2027, then 6.25% of the shares on the first day of each calendar quarter until fully vested, and is exercisable until January 29, 2036.
Flagship Pioneering Fund VII, L.P., a major holder of Foghorn Therapeutics Inc., acquired a large package of derivative securities in a registered direct offering on January 13, 2026. Through this transaction, Flagship Pioneering Fund VII, L.P. received warrants to purchase an aggregate of 4,470,936 shares of Foghorn common stock, made up of 2,235,468 pre-funded warrants, 1,117,734 Series 1 warrants and 1,117,734 Series 2 warrants.
The securities were acquired for a purchase price of $6.7099 per pre-funded warrant and accompanying Series warrants. The Series 1 warrants are initially exercisable at $13.42 per share and the Series 2 warrants at $20.13 per share, with a one-time reset feature before June 30, 2027 if Foghorn issues new capital at a lower weighted-average price, but not below $6.71 per share. All of these warrants are reported as indirectly owned through Flagship Pioneering Fund VII, L.P., with related entities and Noubar B. Afeyan, Ph.D. disclaiming beneficial ownership beyond any pecuniary interest.
Foghorn Therapeutics Inc. (FHTX) disclosed that its Chief Financial Officer, Kristian F. Humer, has resigned from the company effective November 14, 2025. The filing notes that this Form 4 is being submitted solely as a voluntary exit filing, indicating that no further Section 16 ownership reports will be required from this individual. The document does not list any specific stock or option transactions, and focuses instead on formally recording the end of his reporting obligations as an officer of the company.